HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer.

AbstractBACKGROUND:
Eniluracil is an effective inactivator of dihydropyrimidine dehydrogenase, the initial and rate limiting enzyme in the catabolism of fluorouracil. The current study was done to determine the objective tumour response of a 28-day oral regimen of eniluracil-fluorouracil in patients with advanced breast cancer.
PATIENTS AND METHODS:
This was a multicentre, phase II study in patients with anthracycline-refractory (AR) or anthracycline- and taxane-refractory (ATR) advanced breast cancer. Oral eniluracil (10 mg/m2) and fluorouracil (1 mg/m2) were taken twice daily for 28 days of each 35-day treatment course.
RESULTS:
In this study, 106 patients received treatment: 62 patients in the AR stratum and 44 patients in the ATR stratum. The objective tumour response rate in the intent-to-treat population was 18% (95% confidence intervals (CI): 11%-27%), including three complete responses. The response rate was similar in both strata: 19% in the AR and 16% in the ATR stratum. The overall median duration of response was 23.6 weeks. The treatment was well tolerated with a low incidence of grade 3 or 4 toxicities that were considered attributable to study medication.
CONCLUSION:
Treatment with oral eniluracil-fluorouracil was well tolerated by patients with advanced breast cancer. The efficacy data were comparable with those of other published studies in this group of refractory patients.
AuthorsT Skovsgaard, N G Davidson, M J Piccart, D J Richel, J Bonneterre, D T Cirkel, C M Barton, Eniluracil/Fluorouracil Breast Cancer Study Group
JournalAnnals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 12 Issue 9 Pg. 1255-7 (Sep 2001) ISSN: 0923-7534 [Print] England
PMID11697836 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibiotics, Antineoplastic
  • Bridged-Ring Compounds
  • Taxoids
  • taxane
  • eniluracil
  • Uracil
  • Fluorouracil
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Antibiotics, Antineoplastic (pharmacology)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
  • Breast Neoplasms (drug therapy, pathology)
  • Bridged-Ring Compounds (pharmacology)
  • Drug Resistance, Neoplasm
  • Female
  • Fluorouracil (administration & dosage)
  • Humans
  • Middle Aged
  • Taxoids
  • Treatment Outcome
  • Uracil (administration & dosage, analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: